Drug Trial News

RSS

New clinical trial launched to test potential drug that could help immune system combat cancer

Cancer Research UK's Centre for Drug Development, in partnership with Amgen Inc., has launched a new clinical trial to test a drug that could stop a patient's immune system from protecting tumours.

24 Feb 2016

New Botox-like treatment can help runners, cyclists with knee pain

A painful knee condition that affects more than one in eight active people has been treated effectively with a botulinum toxin injection and physiotherapy.

24 Feb 2016

ViiV Healthcare presents positive results from LATTE-2 study at CROI

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the LATTE-2 study at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Headline results were announced in November 2015.

24 Feb 2016

First patient dosed in Novan's Phase 3 program to evaluate efficacy of SB204 Gel in treatment of acne

Novan, Inc. today announced that the first patient has been dosed in its Phase 3 program to evaluate the efficacy and safety of its topical nitric oxide product candidate SB204 Gel in the treatment of acne vulgaris ("acne"). The Company is running two identically designed Phase 3 pivotal trials in parallel and expects to report top-line results in the first half of 2017.

23 Feb 2016

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy.

23 Feb 2016

Cardiac clot-busting drug decreases mortality in hemorrhagic stroke patients

Reporting on the results of a phase III international clinical trial, Johns Hopkins Medicine physicians say use of a cardiac clot-busting drug to treat strokes that cause brain bleeding safely decreased the death rate in patients by 10 percent, compared to a control group receiving saline.

23 Feb 2016

New clinical trial focuses on respiratory drug ambroxol for treatment of Parkinson's disease

A medication approved to treat various respiratory diseases and that has demonstrated neuroprotective effects in preclinical studies is the focus of a new clinical trial for Parkinson's disease.

23 Feb 2016

Pitt experts lead gene therapy clinical trial in Parkinson's disease patients

Experts at the University of Pittsburgh School of Medicine are leading the second arm of a clinical trial using gene therapy to relieve the symptoms of tremor and mobility impairment in patients with Parkinson's disease.

23 Feb 2016

PharmaEssentia to present results of P1101 + ribavirin phase II trial in HCV patients at APASL 2016

PharmaEssentia Corporation announces presentation of the results of the phase II trial for P1101 + ribavirin in patients with chronic HCV genotype 1 infection at the 25th Conference of the Asian Pacific Association for the Study of the Liver, taking place in Tokyo, Japan from February 20 to 24, 2016 (APASL 2016). Data will be presented by the study coordinating investigator Prof. Wan-Long Chuang (Taiwan) at the HCV parallel oral session on Feb 22nd (15:45-17:45).

22 Feb 2016

Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Mast Therapeutics, Inc., a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure today announced that it has completed patient enrollment in its Phase 3 clinical study of vepoloxamer for the treatment of patients with sickle cell disease experiencing vaso-occlusive crisis, known as the EPIC study.

22 Feb 2016

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME).

22 Feb 2016

Naldemedine significantly improves opioid-induced constipation in patients with chronic non-cancer pain

Shionogi today announced pivotal phase III study (COMPOSE I) results showing that once-daily treatment with naldemedine significantly improved opioid-induced constipation (OIC) compared to placebo in patients with chronic non-cancer pain.

22 Feb 2016

FDA-approved Alzheimer's medications may help people quit smoking

Despite several safe drug therapies available to help smokers quit, three-quarters report relapsing within six months of a quit attempt. University of Pennsylvania researchers Rebecca Ashare and Heath Schmidt saw potential for a permanent cessation solution in a class of FDA-approved medications used to improve cognitive impairments from Alzheimer's disease.

19 Feb 2016

Clot-busting drugs decrease mortality in one of worst forms of hemorrhagic stroke

The use of clot-busting drugs to clear blood from the brain's ventricles may be the first effective strategy to decrease mortality for a type of catastrophic bleeding stroke, according to phase-3 clinical trial results announced Thursday at the International Stroke Conference in Los Angeles.

19 Feb 2016

Sanford Health clinical trial testing effectiveness of investigational cancer drug nivolumab

People with Merkel cell, gynecological, gastric and head and neck cancers may be eligible to participate in a clinical trial at Sanford Health testing the effectiveness of an investigational drug called nivolumab.

18 Feb 2016

New drug combination shows promise for patients with non-small cell lung cancer

Lung cancer is the most common cause of cancer-related death in the United States resulting in more than 158,000 deaths each year. With a 5-year survival rate at only 18 percent, the development of new and improved treatment options is needed.

18 Feb 2016

WRAIR begins Phase 1 clinical trial to evaluate MERS vaccine candidate

The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).

17 Feb 2016

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator Pharmaceuticals, Inc. today announced that the Phase 3 clinical trial of VYXEOS (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML) has reached its pre-specified number of events required for the analysis of overall survival.

16 Feb 2016

Experimental vaccine shows effectiveness in Ebola vaccine trial

An experimental vaccine combined with an innovative way of vaccinating people has resulted in an estimated 100 percent efficacy of the vaccine against the Ebola virus in West Africa -- and the approach could establish a new way of responding to outbreaks of emerging pathogens, including the Zika virus.

16 Feb 2016

First patients dosed in Neurotrope's Bryostatin-1 Phase 2b trial for treatment of advanced Alzheimer’s disease

Neurotrope, Inc. today announced that the first patients have been dosed in the Company’s Phase 2b clinical trial of its lead candidate, Bryostatin-1, for the treatment of advanced Alzheimer’s disease.

16 Feb 2016

Drug Trial News

New clinical trial launched to test potential drug that could help immune system combat cancer

New Botox-like treatment can help runners, cyclists with knee pain

ViiV Healthcare presents positive results from LATTE-2 study at CROI

First patient dosed in Novan's Phase 3 program to evaluate efficacy of SB204 Gel in treatment of acne

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Cardiac clot-busting drug decreases mortality in hemorrhagic stroke patients

New clinical trial focuses on respiratory drug ambroxol for treatment of Parkinson's disease

Pitt experts lead gene therapy clinical trial in Parkinson's disease patients

PharmaEssentia to present results of P1101 + ribavirin phase II trial in HCV patients at APASL 2016

Patient enrollment completed in vepoloxamer Phase 3 study for treatment of sickle cell disease

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Naldemedine significantly improves opioid-induced constipation in patients with chronic non-cancer pain

FDA-approved Alzheimer's medications may help people quit smoking

Clot-busting drugs decrease mortality in one of worst forms of hemorrhagic stroke

Sanford Health clinical trial testing effectiveness of investigational cancer drug nivolumab

New drug combination shows promise for patients with non-small cell lung cancer

WRAIR begins Phase 1 clinical trial to evaluate MERS vaccine candidate

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Experimental vaccine shows effectiveness in Ebola vaccine trial

First patients dosed in Neurotrope's Bryostatin-1 Phase 2b trial for treatment of advanced Alzheimer’s disease

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Latest News